RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboESMO 2022 - Regeneron has introduced a "plug and play" oncology strategy to improve checkpoint inhibitor treatments with combination therapies – centered around their PD-1 immune checkpoint inhibitor Libtayo. In a webcast, David Weinreich, M.D., Regeneron’s EVP, global clinical development, noted four approaches: CD3 bispecifics, dubbed Signal 1; CD28 bispecifics, named Signal 2; tumor-targeted biparatopics; and modulating the immune response.
The focus is to “enhance and expand” PD-1 treatment with Regeneron’s combinations to “mix and match best approaches to broadening and deepening anti-tumor activity,” Weinreich said. https://www.biospace.com/article/regeneron-highlights-plug-and-play-oncology-strategy-at-esmo/
[These "plug and play", "enhance and expand" and "mix and match" strategies have already been discussed here involving the use of ONCY's pelareorep in combination with immune checkpoint inhibitors, bispecific antibodies and other cancer therapeutics including CAR-T therapy, and small molecules such as PARP and CDK4,6 inhibitors]